Chemotherapy remains a cornerstone of cancer treatment, yet it's not medically necessary for every diagnosis. Understanding when chemotherapy offers genuine survival benefit, and when it doesn't, empowers patients to make informed decisions. Key Takeaways Chemotherapy necessity depends on cancer type, stage, molecular markers, and patient health, not blanket protocols Genomic testing like Oncotype DX allows 70% of early-stage breast cancer patients to safely avoid chemotherap

When standard cancer treatment stops working, patients face critical decisions about accessing additional treatment pathways through specialized oncology teams, clinical trial networks, molecular tumor boards, and comprehensive second-opinion services that evaluate genomic profiles and emerging therapies. TL;DR Seven in 10 people now survive cancer five years or longer, but treatment resistance requires expert evaluation of additional options including clinical trials, genomi